DOP2005000259A - Compuesto químico y su uso. - Google Patents

Compuesto químico y su uso.

Info

Publication number
DOP2005000259A
DOP2005000259A DO2005P000259A DO2005000259A DOP2005000259A DO P2005000259 A DOP2005000259 A DO P2005000259A DO 2005P000259 A DO2005P000259 A DO 2005P000259A DO 2005000259 A DO2005000259 A DO 2005000259A DO P2005000259 A DOP2005000259 A DO P2005000259A
Authority
DO
Dominican Republic
Prior art keywords
chemical compound
prevention
preparation
treatment
diseases
Prior art date
Application number
DO2005P000259A
Other languages
English (en)
Inventor
Hilmar Bischoff
Heike Gielenhaertwig
Volkhart Li
Carsten Schmeck
Michael Thutewohl
Alexandros Vakalopoulos
Olaf Weber
Martina Wuttke
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004060997A external-priority patent/DE102004060997A1/de
Priority claimed from DE102004061000A external-priority patent/DE102004061000A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of DOP2005000259A publication Critical patent/DOP2005000259A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)

Abstract

LA PRESENTE SOLICITUD SE REFIERE A UN NUEVO DERIVADO DE TETRAHIDROQUINOLINA, A UN PROCEDIMIENTO PARA SU PREPARACION, A SU USO SOLO O EN COMBINACIONES PARA EL TRATAMIENTO Y/O LA PREVENCION DE ENFERMEDADES, ASI COMO A SU USO PARA LA PREPARACIÓN DE FARMACOS, ESPECIALMENTE COMO INHIBIDOR DE LA PROTEINA DE TRANSFERENCIA DE ESTER DE COLESTEROL (CETP) PARA EL TRATAMIENTO Y/O LA PREVENCION DE ENFERMEDADES CARDIOVASCULARES, ESPECIALMENTE DE HIPOLIPOPROTEINEMIAS, DISLIPIDEMIAS, HIPERTRIGLICERIDEMIAS, HIPERLIPIDEMIAS, HIPERCOLESTEROLEMIAS Y ARTERIOSCLEROSIS.
DO2005P000259A 2004-12-18 2005-12-16 Compuesto químico y su uso. DOP2005000259A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004060997A DE102004060997A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004061000A DE102004061000A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung

Publications (1)

Publication Number Publication Date
DOP2005000259A true DOP2005000259A (es) 2006-11-15

Family

ID=35841894

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2005P000259A DOP2005000259A (es) 2004-12-18 2005-12-16 Compuesto químico y su uso.

Country Status (27)

Country Link
US (2) US8124775B2 (es)
EP (1) EP1828137B1 (es)
JP (1) JP5132317B2 (es)
KR (1) KR20070090248A (es)
AR (1) AR055011A1 (es)
AT (1) ATE555097T1 (es)
AU (1) AU2005315770B2 (es)
BR (1) BRPI0519602A2 (es)
CA (1) CA2591397A1 (es)
CU (1) CU23452B7 (es)
CY (1) CY1112887T1 (es)
DK (1) DK1828137T3 (es)
DO (1) DOP2005000259A (es)
ES (1) ES2384980T3 (es)
GT (1) GT200500377A (es)
IL (1) IL184008A (es)
MA (1) MA29100B1 (es)
MX (1) MX2007007188A (es)
NO (1) NO20073146L (es)
PE (1) PE20060767A1 (es)
PL (1) PL1828137T3 (es)
PT (1) PT1828137E (es)
RU (1) RU2393151C2 (es)
SI (1) SI1828137T1 (es)
TW (1) TW200635900A (es)
UY (1) UY29276A1 (es)
WO (1) WO2006063828A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007007187A (es) * 2004-12-18 2007-08-14 Bayer Healthcare Ag Derivados de (5s)-3-[(s)-fluoro-(4-trifluorometilfenil)metil]-5,6, 7,8-tetrahidroquinolin-5-ol y su uso como inhibidores de la proteina de transferencia de ester de colesterol.
DE102006012548A1 (de) * 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
PL2268644T3 (pl) * 2008-03-05 2012-01-31 Boehringer Ingelheim Int Tricykliczne pochodne piperydyny, leki zawierające te związki, ich zastosowanie i sposoby ich wytwarzania
JP5780528B2 (ja) 2010-02-19 2015-09-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 三環式ピリジン誘導体、このような化合物を含有する医薬、それらの使用、およびそれらの調製方法
RU2572606C2 (ru) * 2010-07-09 2016-01-20 Дайити Санкио Компани, Лимитед Замещенное пиридиновое соединение
US20130053404A1 (en) 2011-02-17 2013-02-28 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
AR087577A1 (es) 2011-08-17 2014-04-03 Boehringer Ingelheim Int Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparacion
ES2599757T3 (es) 2012-01-06 2017-02-03 Daiichi Sankyo Company, Limited Sales de aducto de ácido de un compuesto de piridina sustituido como inhibidores de la proteína de transferencia de ésteres de colesterilo (PTEC)
KR102456013B1 (ko) 2014-07-30 2022-10-18 에프. 호프만-라 로슈 아게 고밀도 지질단백질(hdl)-상승 제제 또는 hdl-모방 제제에 의한 치료법에 대한 반응성을 예측하기 위한 유전 표지

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
DE19704244A1 (de) 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
DE19741051A1 (de) * 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
MA24643A1 (fr) * 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
DE19935966A1 (de) 1999-07-30 2001-02-01 Bayer Ag Verfahren zur Reduktion von Ketoalkoholen
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10250687A1 (de) 2002-10-31 2004-05-13 Bayer Ag 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung
MX2007007187A (es) * 2004-12-18 2007-08-14 Bayer Healthcare Ag Derivados de (5s)-3-[(s)-fluoro-(4-trifluorometilfenil)metil]-5,6, 7,8-tetrahidroquinolin-5-ol y su uso como inhibidores de la proteina de transferencia de ester de colesterol.

Also Published As

Publication number Publication date
AR055011A1 (es) 2007-08-01
US8124775B2 (en) 2012-02-28
JP5132317B2 (ja) 2013-01-30
ES2384980T3 (es) 2012-07-16
CA2591397A1 (en) 2006-06-22
AU2005315770A1 (en) 2006-06-22
US20120142728A1 (en) 2012-06-07
MX2007007188A (es) 2007-08-14
CY1112887T1 (el) 2016-04-13
RU2393151C2 (ru) 2010-06-27
PE20060767A1 (es) 2006-09-10
IL184008A0 (en) 2007-10-31
EP1828137B1 (de) 2012-04-25
EP1828137A1 (de) 2007-09-05
GT200500377A (es) 2006-11-09
UY29276A1 (es) 2006-07-31
JP2008524145A (ja) 2008-07-10
PL1828137T3 (pl) 2012-09-28
SI1828137T1 (sl) 2012-08-31
BRPI0519602A2 (pt) 2009-02-25
IL184008A (en) 2012-03-29
MA29100B1 (fr) 2007-12-03
PT1828137E (pt) 2012-07-04
AU2005315770B2 (en) 2011-12-08
RU2007127127A (ru) 2009-01-27
TW200635900A (en) 2006-10-16
KR20070090248A (ko) 2007-09-05
US20080255068A1 (en) 2008-10-16
NO20073146L (no) 2007-09-18
CU23452B7 (es) 2009-12-01
WO2006063828A1 (de) 2006-06-22
ATE555097T1 (de) 2012-05-15
DK1828137T3 (da) 2012-07-23

Similar Documents

Publication Publication Date Title
DOP2005000259A (es) Compuesto químico y su uso.
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
CL2008000785A1 (es) Compuestos derivados de 4-((7,7-difluoro-5-metil-6-oxo-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-il)amino)-3-metoxibenzamida; compuesto intermediario; composicion farmaceutica, utiles para tratar el cancer.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2008001457A1 (es) Compuestos derivados de 6-(piridin-3-il)quinolina, inhibidores de la pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de cancer en un humano que lo necesite.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
WO2007115821A3 (en) Organic compounds
WO2007022518A8 (en) New uses of glucoregulatory proteins
WO2009156462A3 (en) Organic compounds
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
CR10157A (es) Compuestos químicos
ECSP099410A (es) Adsorbente de fosfato a base de hierro (iii)-carbohidrato
EA200700982A1 (ru) Производные хинолина и изохинолина, замещённые в 5-ом положении, способ их получения и их применение в качестве противовоспалительных средств
ATE453384T1 (de) Neue dosierformulierung
CL2007002856A1 (es) Compuestos derivados de pirazolo(1,5)pirimidina; composicion farmaceutica qu lo comprende;y su uso para tratar el cancer.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2011001331A1 (es) Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo.
CL2011001078A1 (es) Compuestos derivados de espirodihidrotetraazabenzoazuleno; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o tratamiento de dismenorrea, disfuncion sexual, hipertension, cirrosis hepatica y esquizofrenia entre otras.
ATE496913T1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.